Skip to content

Author

B. Neuen

We have 7 of 273 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Abstract 6316: Inflammatory Risk and Cardio-Renal Outcomes in Adults with Chronic Kidney Disease: A Nationwide Study

Introduction: The prognostic burden of inflammation in chronic kidney disease (CKD) remains poorly characterized, with prior small-scale studies yielding conflicting estimates of the association between elevated C-reactive protein (CRP) and cardio-renal outcomes. Methods: We conducted an observational study of...

Katherine R. Tuttle, F. Mazhar, Minjung Han et al. · 0 citations
Open access Aug 2026

Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis.

BACKGROUND AND AIMS Hypertension is a common attributable cause of chronic kidney disease (CKD). Mineralocorticoid receptor overactivation can lead to hypertension and contributes to CKD progression. In FIND-CKD, finerenone reduced kidney function decline in participants with CKD without diabetes. This prespecified FIN...

H. Heerspink, Jelle M. Beernink, R. Agarwal et al. · 0 citations
Open access Oct 2026

High sensitivity C-reactive protein and the risk of cardio-kidney outcomes in adults with moderate to severe chronic kidney disease: a nationwide study.

BACKGROUND AND HYPOTHESIS The burden and prognostic significance of inflammation in chronic kidney disease (CKD) remains poorly characterized, with prior studies yielding conflicting estimates of the association between elevated high-sensitivity C-reactive protein (hsCRP) and cardio-kidney outcomes. METHODS Observati...

F. Mazhar, Minjung Han, Katherine R. Tuttle et al. · 0 citations
Review Open access Sep 2026

ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome.

KEY POINTS The cardiovascular-kidney-metabolic (CKM) syndrome framework has important implications in the care of people with kidney diseases. Cardiovascular screening is important in people with kidney diseases, but the approach may differ in this high-risk population. Multiple pharmacotherapies for CKM syndrome offer...

N. Bansal, P. Bjornstad, A. Bress et al. · 3 citations
Oct 2026

Pharmacological treatment strategies to prevent heart failure across the cardiovascular-kidney-metabolic spectrum: an EJHF Expert Consensus Statement.

Heart failure (HF) remains a major cause of morbidity, mortality, and increased healthcare costs worldwide, and is recognized as the result of progressive cardiovascular-kidney-metabolic (CKM) syndrome. Obesity, type 2 diabetes, chronic kidney disease, hypertension, and atherosclerotic cardiovascular disease frequently...

R. Inciardi, A. Abdin, M. Abdelhamid et al. · 0 citations
Review Sep 2026

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes

Investigating treatments for CKD possess anti-inflammatory properties that might contribute to their previously established clinical benefits, including renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocortico...

Katherine R. Tuttle, Mehmet Kanbay, Radica Z. Alicic et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.